Molex expands inhalation capabilities with acquisition of Vectura and Chippenham site
What happened
Phillips Medisize, a drug delivery device maker and Molex company, acquired the complete footprint of its Chippenham, England, site. This move expands the company's Global Inhalation Center of Excellence, which also includes its location in Cambridge, England. The acquisition builds on the 2025 purchase of Vectura Group Ltd., adding inhalation capabilities to Phillips Medisize's existing offerings.
Why it matters
Phillips Medisize projects substantial growth in inhalation revenue over the next five years. Securing the full Chippenham site provides long-term operational control for formulation development and clinical trial supply manufacturing. The expansion adds capacity for complex inhaled small molecule and biologic therapies.
Who's involved
- MolexParent company of Phillips Medisize, the acquiring entity.
- VecturaNorwegian company whose inhalation capabilities were added to Phillips Medisize.
- ChippenhamTown in Wiltshire, England, where the acquired site is located.
- Charlie SchumacherVice president of inhalation therapies at Phillips Medisize.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- MolexSpeculative
Growth of Phillips Medisize might boost parent company revenue.
- Charlie SchumacherSpeculative
The expansion of the Global Inhalation Center of Excellence may support his division's projected revenue growth.
- WiltshireSpeculative
Increased industrial capacity in Chippenham could boost regional demand.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Molex expansion in Chippenham could boost Wiltshire Council's tax baseWiltshire Council may benefit from Molex's major industrial expansion in ChippenhamPossible
- The expansion of high-tech drug delivery capacity could boost Great Britain's manufacturing sectorThe expansion of high-tech drug delivery capacity could boost Great Britain's manufacturing sector.Possible